Aarti Drugs Limited
NSE: AARTIDRUGS · Pharmaceuticals
Snapshot
Unlock Aarti Drugs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarti Drugs Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company serves a diverse range of therapeutic categories including anti-inflammatory, antibiotics, and antidiabetics, while also providing contract manufacturing services.
Business Model
The company generates revenue through the large-scale production and sale of APIs and intermediates to global pharmaceutical manufacturers. Additionally, it leverages its chemical expertise to produce specialty chemicals and offers contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by a robust pipeline of products under development, including treatments for cardiovascular diseases, alcoholism, and diabetes. The company continues to expand its portfolio of specialty chemicals and enhance its contract manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance could lead to export bans or facility shutdowns.
- Raw Material Price Volatility. Fluctuations in the costs of key chemical inputs and intermediates can significantly impact operating margins.
- Geopolitical and Trade Risks. As an exporter, the company is susceptible to changes in international trade policies, tariffs, and currency exchange rate volatility.
- R&D Execution Risk. The successful commercialisation of the company's development pipeline depends on timely regulatory approvals and market adoption of new therapeutic products.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Aarti Drugs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,260 Cr
TTM · standalone
NET PROFIT
₹169 Cr
TTM · standalone
EPS
₹18.55
TTM · standalone
RETURN ON EQUITY
13.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.0%
TTM · standalone
P/E
22.6x
Q4 FY26 · standalone
EV/EBITDA
16.1x
Q4 FY26 · standalone
EBITDA MARGIN
11.6%
TTM · standalone
NET PROFIT MARGIN
7.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Aarti Drugs LimitedAARTIDRUGS | 3,074 | 22.64 | 16.14 | 4.0% | 11.6% | 13.1% | 13.0% | -19.3% |
Senores Pharmaceuticals Ltd.SENORES | 3,407 | 55.05 | 32.37 | — | 33.2% | 14.8% | 17.8% | +135.5% |
RPG Life Sciences LimitedRPGLIFE | 2,955 | 41.96 | 27.43 | 8.3% | 24.4% | 21.0% | 27.6% | +9.9% |
Gujarat Themis Biosyn Ltd.GUJTHEM | 2,900 | 112.93 | 45.50 | 33.7% | 45.7% | 21.6% | 24.4% | -0.3% |
Gufic Biosciences LimitedGUFICBIO | 2,817 | 60.67 | 27.39 | 15.2% | 16.3% | 10.4% | 15.5% | +1.9% |
Orchid Pharma LimitedORCHPHARMA | 2,615 | 269.06 | 76.30 | -12.0% | 9.4% | 1.6% | 2.3% | +44.1% |
As of Q4 FY26
Financials
Aarti Drugs Limited
NSE: AARTIDRUGS · Pharmaceuticals
Snapshot
Unlock Aarti Drugs Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Aarti Drugs Limited is a pharmaceutical company that manufactures active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. The company serves a diverse range of therapeutic categories including anti-inflammatory, antibiotics, and antidiabetics, while also providing contract manufacturing services.
Business Model
The company generates revenue through the large-scale production and sale of APIs and intermediates to global pharmaceutical manufacturers. Additionally, it leverages its chemical expertise to produce specialty chemicals and offers contract manufacturing services to third-party clients.
Growth Outlook
Growth is driven by a robust pipeline of products under development, including treatments for cardiovascular diseases, alcoholism, and diabetes. The company continues to expand its portfolio of specialty chemicals and enhance its contract manufacturing capabilities.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance could lead to export bans or facility shutdowns.
- Raw Material Price Volatility. Fluctuations in the costs of key chemical inputs and intermediates can significantly impact operating margins.
- Geopolitical and Trade Risks. As an exporter, the company is susceptible to changes in international trade policies, tariffs, and currency exchange rate volatility.
- R&D Execution Risk. The successful commercialisation of the company's development pipeline depends on timely regulatory approvals and market adoption of new therapeutic products.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Aarti Drugs Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹2,260 Cr
TTM · standalone
NET PROFIT
₹169 Cr
TTM · standalone
EPS
₹18.55
TTM · standalone
RETURN ON EQUITY
13.1%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
13.0%
TTM · standalone
P/E
22.6x
Q4 FY26 · standalone
EV/EBITDA
16.1x
Q4 FY26 · standalone
EBITDA MARGIN
11.6%
TTM · standalone
NET PROFIT MARGIN
7.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.4x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26